Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NanoCarrier Co., Ltd. ( (JP:4571) ) has provided an announcement.
Nano Holdings, Inc., a Japan-based healthcare value creation platform, focuses on advancing Japanese-origin biomedical technologies to global markets by aligning scientific innovation with international business expertise. The company leverages cross-border collaboration to develop and scale novel therapeutic platforms, aiming to enhance its presence in the global healthcare and biotech ecosystem.
Nano Holdings announced that the first patient has been dosed in a Phase 1 first-in-human trial of its RUNX1 mRNA therapy for knee osteoarthritis, conducted in Australia through its local subsidiary PrimRNA AU Pty Ltd. The trial, the world’s first intra-articular mRNA therapeutic injection into the knee for osteoarthritis, underscores a strategic Australia–Japan collaboration and could position the company at the forefront of disease-modifying regenerative treatments in a large, underserved osteoarthritis market.
RUNX1 mRNA is designed to activate regenerative pathways within cartilage and directly target the underlying disease mechanisms in osteoarthritis rather than just alleviating symptoms. If successful, this approach could eventually offer an alternative to current symptomatic therapies such as NSAIDs, steroid or hyaluronic acid injections, and may delay or reduce the need for total joint replacement surgery in knee osteoarthritis patients.
The most recent analyst rating on (JP:4571) stock is a Hold with a Yen181.00 price target. To see the full list of analyst forecasts on NanoCarrier Co., Ltd. stock, see the JP:4571 Stock Forecast page.
More about NanoCarrier Co., Ltd.
Nano Holdings, Inc., listed on the TSE Growth Market, operates as a healthcare-focused value creation platform that supports the commercialization of Japanese-origin medical technologies globally. The company brings together executives, scientists, and investors to build businesses that can achieve worldwide recognition and maximize the value of innovative healthcare technologies.
YTD Price Performance: 30.99%
Average Trading Volume: 853,973
Technical Sentiment Signal: Hold
Current Market Cap: Yen14.02B
Learn more about 4571 stock on TipRanks’ Stock Analysis page.